

Abortive HIV-1 RNA transcripts are detected in serum of people living with HIV during long-term effective antiretroviral therapy

Stefanie Kroeze^{1,2}, Shirley Man^{1,2}, Jade Jansen^{1,2}, Carla M.S. Ribeiro^{1,2}, Teunis B.H. Geijtenbeek^{1,2} and Neeltje A. Kootstra^{1,2}


¹ Amsterdam UMC location University of Amsterdam, Department of Experimental Immunology, Meibergdreef 9, Amsterdam, The Netherlands;

² Amsterdam institute for Infection and Immunity, Amsterdam, The Netherlands


Introduction

A major focus of HIV-cure research is to find novel methods to reduce or eliminate the viral reservoir, and therefore it is important to monitor the dynamics of the viral reservoir in people living with HIV (PLWH). Established assays to measure the viral reservoir use cells from PLWH, which requires intricate handling and labor intensive procedures. The identification of suitable targets and markers of the HIV-reservoir are therefore a main topic of HIV-cure research. The transactivation-response element (TAR) RNA has been proposed as potential biomarker of the latent HIV-reservoir. TAR-RNA is a short abortive HIV-1 RNA transcript and is expressed in latently infected cells and can be detected in serum. However, the dynamics of abortive HIV-1 RNA expression during long term therapy remains largely unknown. Here, we established a qPCR assay to monitor abortive HIV-1 RNA transcripts in serum of PLWH and investigated the dynamics before and during effective antiretroviral therapy.

Figure 1. Shows the location of the transactivation-response element (TAR) in the HIV-genome, and the processing of TAR-RNA during active transcription and during latency



Methods



1 Participant selection
Pre-cART (0), and 1, 2, and 5 years on-cART serum samples from thirty-two participants enrolled in the Amsterdam Cohort Studies who had been living with HIV for at least 2 years prior to starting cART, and had an undetectable viral load after 1 year of cART and maintained an undetectable viral load thereafter, were selected.

Laboratory methods
RNA was isolated from serum samples, cDNA was synthesized and a qPCR was used to measure abortive HIV-1 RNA.

Statistical analysis

- Repeated measures ANOVA with post-hoc pairwise comparison was used to investigate the time-course effect.
- Univariable linear regression analysis was used to investigate associations of abortive HIV-1 RNA at the different timepoints and pre-ART variables: CD4+ T-cell count, CD8+ T-cell count, CD4/CD8 ratio and viral load.

Results

1 Participant characteristics

Age (median-IQR)	43 (36-49)
Start cART '96-'98	30 (94%)
Baseline CD4+ T-cell count	354 (246 - 460)
Baseline CD8+ T-cell count	950 (765 - 1186)
CD4/CD8 ratio	0.34 (0.22-0.48)
Baseline viral load (log ₁₀ copies/mL)	4.5 (4.1 - 4.8)

Table 1. Participant characteristics. Summary statistics are presented as median (IQR) or n (%).

3 Associations of baseline variables and abortive HIV-1 transcripts




Figure 3. The results of the univariable regression analysis to investigate the association between pre-cART variables and log₁₀ abortive HIV-1 RNA transcripts pre-cART and at 1, 2 and 5 years of cART.

2 Dynamics of abortive HIV-1 RNA transcripts




Figure 2. Dynamics of abortive HIV-1 RNA transcripts during the first five years of cART. A repeated measures ANOVA with post-hoc pairwise comparisons was used to investigate the time-course effect. Squares indicate the median and whiskers the interquartile range per time point. Individual data points are presented in colors corresponding to the pre-cART (0) quantiles.

Conclusions

Here we show that abortive HIV-1 RNA is detected in serum during long term therapy and represents a potential biomarker for monitoring latent viral reservoir. Future studies will determine whether serum-derived abortive HIV-1 RNA levels are associated with cellular viral reservoir measurements.

Funding & contact

Contact: s.kroeze@amsterdamumc.nl
This research is part of the HIV-CURE program. Funding for the Target2Cure project was provided by Aidsfonds/Health Holland